Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 2Neoplasms 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Glioblastoma 2Recurrence 1Lymphoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Cancers 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × Crizotinib × Clear all
NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡